NCC-13-01Phase I trial of OXIRI [oxaliplatin (O), xeloda (X) and irinotecan (I)] treatment in patients with advanced and/or metastatic pancreatic adenocarcinoma
A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3
HER2+, Hormone Receptor+,LABC MBC
TNBCLABCMBC1st or 2nd line
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000